Hepatitis B Virus (HBV)

Tag: malignancy

Crohn’s disease

Anti -TNF therapy and malignancy – A critical review: CONCLUSIONS

We have provided an analysis of the association between anti-TNF-a therapy and a possible increase in solid tumour and lymphoma development. At this time the database remains relatively small. Furthermore, the studies were clearly not powered to detect any causal relationship between anti-TNF-a therapy and a relatively rare event such as cancer. Analysis of the […]

Crohn’s disease

Anti -TNF therapy and malignancy – A critical review: INCIDENCE OF MALIGNANCIES Part 5

In the three patients with rheumatoid arthritis who developed lymphomas during and for three years following the infliximab clinical trials, theirdiseases included two B cell lymphomas and one case of HD. All of these patients had a long history ofdisease activity (ranging from five to 36 years) and had histories of priortreatment with immunosuppressive agents. […]

A summary of infliximab-treated patients with lymphoproliferative malignancies

Anti -TNF therapy and malignancy – A critical review: INCIDENCE OF MALIGNANCIES Part 4

Incidence of lymphomas in clinical trials of infliximab therapy: Among the 770 infliximab-treated patients and 192 patients treated with placebo who participated in the infliximab clinical trials, one infliximab-treated patient with Crohn’s disease and three infliximab-treated patients with rheumatoid arthritis developed a lymphoma (NHL or HD) either during the clinical trial or during the three-year […]

Number of patients with non-lymphoma malignancies

Anti -TNF therapy and malignancy – A critical review: INCIDENCE OF MALIGNANCIES Part 3

Incidence of solid tumours and nonmelanoma skin cancers in clinical trials of infliximab therapy: In all infliximab clinical trials and excluding nonmelanoma skin cancers, 12 infliximab-treated and two placebo-treated patients developed solid tumours during the studies or during the three-year prospective follow-up period. This corresponds to incidences of 0.0063 and 0.0068 per patient-year for infliximab-treated […]

Crohn’s disease

Anti -TNF therapy and malignancy – A critical review: INCIDENCE OF MALIGNANCIES Part 2

Interestingly, similar incidences in malignancy were reported during clinical trials of another anti-TNF agent, etanercept (Enbrel; Immunex, USA). Etanercept is a dimeric fusion protein (comprising the extracellular ligand-binding portion of the human p75 TNF receptor linked to the Fc portion of human IgG1) that is approved for the treatment of patients with rheumatoid arthritis. In […]

Crohn’s disease

Anti -TNF therapy and malignancy – A critical review: INCIDENCE OF MALIGNANCIES Part 1

The information presented in subsequent sections of this article derives from validated data reported during the study or during the three-year prospective follow-up period, as of December 2000. A large number of patients continue to be monitored in the three-year prospective safety follow-up study. Incidences are reported only for validated data for which patient-years could […]

Crohn’s disease

Anti -TNF therapy and malignancy – A critical review: RISK FACTORS FOR MALIGNANCY IN INFLAMMATORY DISEASES Part 4

A number of observational studies have been performed in attempts to clarify the association between Crohn’s disease and lymphoma, but have arrived at conflicting or inconclusive results. In an inception cohort of 216 patients with Crohn’s disease followed in Olmsted County, Minnesota, one case of primary small bowel lymphoma occurred, yielding a standardized incidence ratio […]

Tags